Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by Johnandrose22 on Jun 11, 2021 7:11am

Good News

Theralase Launches Seventh US Clinical Site....Treats first US patient.
Comment by Johnandrose22 on Jun 11, 2021 10:03am
Shaun Shirazi, PhD..”It is exciting to see Theralase clear another hurdle...and move one step closer to achieving its next milestone of enrolling and treating twenty five patients in early 2021”. Reading Dr. Shirazi’s words gives me increasing confidence that “early 2021” is understood as the first half of this year, ie the end of this month. I anticipate the company sharing that it has reached ...more  
Comment by chry200030 on Jun 11, 2021 11:09am
How many patients have they enrolled now, not including China?
Comment by Yajne on Jun 11, 2021 12:07pm
It is great that TLT continues to reference the 3 treated with full dose in Ph1b, particularly since P5 & 6 were CR at 18 months and probably still are CR although no recent data reported on them. The Ph1b full dose patients do not count toward the first 25 required in StudyII for FDA consideration of BTD. However, the fact that TLT continues to reference them in recent nr's has me hopeful ...more  
Comment by 99942Apophis on Jun 11, 2021 12:44pm
Johnandrose22 wrote Shaun Shirazi, PhD..”It is exciting to see Theralase clear another hurdle...and move one step closer to achieving its next milestone of enrolling and treating twenty five patients in early 2021”. Reading Dr. Shirazi’s words gives me increasing confidence that “early 2021” is understood as the first half of this year, ie the end of this month. I anticipate the company sharing ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250